Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Patent law (3)
- Broadcasting (1)
- Clearly erroneous (1)
- Copyright law (1)
- Copyright loopholes (1)
-
- Cybor Corp. v. FAS Technologies Inc. (1)
- De novo review (1)
- Disclosure (1)
- Drugs (1)
- Empirical studies (1)
- Exclusivity (1)
- Federal Circuit (1)
- First-to-file (1)
- First-to-invent (1)
- Food and Drug Administration (1)
- Food and Drug Administration Amendment Act of 2007 (1)
- Incentives (1)
- Innovation (1)
- Inventions (1)
- Juries (1)
- Law reform (1)
- Markman v. Westview Instruments Inc. (1)
- Music (1)
- Novelty (1)
- Patent applications (1)
- Patent claims (1)
- Patent prosecutions (1)
- Patent reform (1)
- Patent system (1)
- Pharmaceuticals (1)
Articles 1 - 4 of 4
Full-Text Articles in Law
Is Novelty Obsolete - Chronicling The Irrelevance Of The Invention Date In U.S. Patent Law, Dennis D. Crouch
Is Novelty Obsolete - Chronicling The Irrelevance Of The Invention Date In U.S. Patent Law, Dennis D. Crouch
Michigan Telecommunications & Technology Law Review
This paper presents a normative study of patent prosecution by examining the role that invention-date-based novelty rights play in U.S. patent law. Three sources inform the primary results: the prosecution history files of 21,000+ patent applications filed in the past decade; a survey of 1,000+ patent practitioners regarding their use of the novelty provisions of the Patent Act; and a collection of 11,000,000+ prior art references cited in recently-issued patents. Additional compilations of prosecution file histories for patents identified as either (1) valuable or (2) worthless supplement these data sets and allow for an evaluation of the differential importance of …
Why Fdca Section 505(U) Should Not Concern Us Greatly, Kyle Faget
Why Fdca Section 505(U) Should Not Concern Us Greatly, Kyle Faget
Michigan Telecommunications & Technology Law Review
Among the many amendments found in the Food and Drug Administration Amendment Act of 2007 (FDAAA) is a provision at the end of the act, Section 505(u), which grants chiral switches five years of market exclusivity under certain circumstances. Prior to Congressional enactment of the FDAAA, the Food and Drug Administration (FDA) refused to award new chemical entity (NCE) status to enantiomers of previously approved racemic mixtures. The FDA defines a new chemical entity ("NCE") as a drug that contains no active moiety that has been approved by the FDA in any other application submitted under Section 505(b) of the …
The Super Brawl: The History And Future Of The Sound Recording Performance Right, Brian Day
The Super Brawl: The History And Future Of The Sound Recording Performance Right, Brian Day
Michigan Telecommunications & Technology Law Review
On February 4, 2009, Senator Patrick Leahy introduced the Performance Rights Act ("PRA") to the Senate, joined by Representative John Conyers in the House of Representatives. Thirty-eight years after sound recordings were first granted federal copyright protection against unauthorized reproduction and distribution--and more than ten years after gaining a limited digital performance right--legislation is pending that would once again expand the scope of sound recording copyright to encompass terrestrial radio broadcasts. Historically, such broadcasts have been exempt from sound recording performance royalties.[...] Instead of (or in addition to) seeking remuneration from terrestrial radio stations, this Note suggests that sound recording …
Appellate Review Of Patent Claim Construction: Should The Federal Circuit Be Its Own Lexicographer In Matters Related To The Seventh Amendment, Eileen M. Herlihy
Appellate Review Of Patent Claim Construction: Should The Federal Circuit Be Its Own Lexicographer In Matters Related To The Seventh Amendment, Eileen M. Herlihy
Michigan Telecommunications & Technology Law Review
The Federal Circuit stated in an en banc decision in Cybor Corp. v. FAS Technologies, Inc. that the construction of patent claims is "a purely legal issue," and is therefore subject to de novo review on appeal. The Cybor decision reaffirmed the position of the majority of the Federal Circuit which had been announced in its en banc Markman decision, and proclaimed that the de novo standard of review is supported by the Supreme Court's Markman decision, a Seventh Amendment opinion. However, Cybor included strong opposition to a de novo standard of review from some of the judges of the …